MDPI and ACS Style
de la Cruz-Ojeda, P.; Schmid, T.; Boix, L.; Moreno, M.; Sapena, V.; Praena-Fernández, J.M.; Castell, F.J.; Falcón-Pérez, J.M.; Reig, M.; Brüne, B.;
et al. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Cells 2022, 11, 2673.
https://doi.org/10.3390/cells11172673
AMA Style
de la Cruz-Ojeda P, Schmid T, Boix L, Moreno M, Sapena V, Praena-Fernández JM, Castell FJ, Falcón-Pérez JM, Reig M, Brüne B,
et al. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Cells. 2022; 11(17):2673.
https://doi.org/10.3390/cells11172673
Chicago/Turabian Style
de la Cruz-Ojeda, Patricia, Tobias Schmid, Loreto Boix, Manuela Moreno, Víctor Sapena, Juan M. Praena-Fernández, Francisco J. Castell, Juan Manuel Falcón-Pérez, María Reig, Bernhard Brüne,
and et al. 2022. "miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma" Cells 11, no. 17: 2673.
https://doi.org/10.3390/cells11172673